BioCentury
ARTICLE | Finance

Dec. 9 Quick Takes: Nuance leads bolus of venture rounds for China’s innovators; plus launches for Hillhouse’s Overland, OSI’s PepGen and Atlas’ Vigil and more

December 10, 2020 2:03 AM UTC

CBC portfolio company Nuance closes $181M series D
Nuance Biotech raised $181 million in a series D round led by RTW Investments and GT Fund with participation by existing investors CBC Group, Matrix Partners China and HBM Healthcare Investments and new investor Beijing Konruns Pharmaceutical Co. Ltd. (Shanghai:603590). The six-year-old Shanghai-based company, which is led by founder and CEO Mark Lotter, focuses on iron deficiency, pain management and respiratory disease.

Hillhouse’s Mu and Zhang launch start-up Overland
Backed by Hillhouse Capital, Overland Pharmaceuticals made its official debut Wednesday to build a therapeutics pipeline via partnerships. Hillhouse Venture Partners Hua Mu and Ed Zhang will lead the company as interim CEO and CMO, and COO and CBO, respectively. Overland, which has offices in Shanghai, Beijing and Boston, has yet to disclose details on its funding and pipeline...